Alex Manick is an Associate Principal focused on venture and growth stage investments for Schooner Capital, a Boston-based multi-strategy firm. She currently serves as a Director at Remedy Plan Therapeutics and a Board Observer at Censinet and eXIthera. Prior to Schooner, she worked as a process engineer for MIT spin-out start-up 1366 Technologies, analyzed automobile manufacturing practices for the CTO at Tesla Motors, and consulted for various early stage tech companies. Alex holds an MBA from Stanford and a BS in Materials Science from MIT. She remains involved with the MIT community as a mentor for the Sandbox Innovation Fund.
Associate Principal, Schooner Capital